Hengrui Receives Clinical Clearance for HRS-5041 in Prostate Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance from...
Porton Advanced and Cellstore Partner to Optimize Cell Therapy Drug Cryopreservation
China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. and Cellstore announced today...
ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...
Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million
China-based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) announced that its subsidiary, Shandong Luoxin Pharmaceutical...
Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the out-licensing collaboration between its subsidiary...
Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China
Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment...
Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma
French pharmaceutical major Sanofi (NASDAQ: SNY) reported that the U.S. Food and Drug Administration (FDA)...
Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion
Switzerland-headquartered Sandoz (SWX: SDZ) announced that it has signed a non-binding term sheet with Germany’s...
Zhaoke Ophthalmology’s Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma
China-based Zhaoke Ophthalmology Ltd (HKG: 6622), a leader in ophthalmic solutions, today announced that its...
Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion
China-based Zhaoke Ophthalmology (HKG: 6622) announced the signing of a Memorandum of Agreement (MOA) with...
Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions
China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...
GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines
UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales...
CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...
HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL
The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...
Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials
Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...
Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...
LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics
LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...
Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...
China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment
China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...